- Home
- MUJ vs PHAR Comparison
MUJ vs PHAR Comparison
Compare MUJ & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MUJ
- PHAR
- Stock Information
- Founded
- MUJ 1998
- PHAR 1988
- Country
- MUJ United States
- PHAR Netherlands
- Employees
- MUJ N/A
- PHAR N/A
- Industry
- MUJ Investment Bankers/Brokers/Service
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- MUJ Finance
- PHAR Health Care
- Exchange
- MUJ Nasdaq
- PHAR Nasdaq
- Market Cap
- MUJ 606.3M
- PHAR 1.0B
- IPO Year
- MUJ N/A
- PHAR N/A
- Fundamental
- Price
- MUJ $11.42
- PHAR $13.89
- Analyst Decision
- MUJ
- PHAR Strong Buy
- Analyst Count
- MUJ 0
- PHAR 3
- Target Price
- MUJ N/A
- PHAR $30.00
- AVG Volume (30 Days)
- MUJ 108.0K
- PHAR 11.8K
- Earning Date
- MUJ 01-01-0001
- PHAR 10-23-2025
- Dividend Yield
- MUJ 4.36%
- PHAR N/A
- EPS Growth
- MUJ N/A
- PHAR N/A
- EPS
- MUJ N/A
- PHAR N/A
- Revenue
- MUJ N/A
- PHAR $339,836,000.00
- Revenue This Year
- MUJ N/A
- PHAR $16.63
- Revenue Next Year
- MUJ N/A
- PHAR $6.77
- P/E Ratio
- MUJ N/A
- PHAR N/A
- Revenue Growth
- MUJ N/A
- PHAR 22.44
- 52 Week Low
- MUJ $9.74
- PHAR $7.31
- 52 Week High
- MUJ $11.70
- PHAR $17.08
- Technical
- Relative Strength Index (RSI)
- MUJ 70.87
- PHAR 52.44
- Support Level
- MUJ $10.88
- PHAR $13.51
- Resistance Level
- MUJ $11.49
- PHAR $15.61
- Average True Range (ATR)
- MUJ 0.09
- PHAR 0.92
- MACD
- MUJ 0.04
- PHAR -0.12
- Stochastic Oscillator
- MUJ 88.52
- PHAR 30.89
About MUJ Blackrock MuniHoldings New Jersey Quality Fund Inc.
BlackRock MuniHoldings New Jersey Quality Fund Inc is a closed-end management investment company. The investment objective of the company is to provide shareholders with current income exempt from U.S. federal income tax and New Jersey personal income taxes. The fund invests in a portfolio of long-term, investment-grade New Jersey municipal obligations.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.